What is Posicor used for?

Posicor is indicated for Angina pectoris, Hypertensive disorder.

What development phase is Posicor in?

Posicor is FDA-approved (marketed).

What is the generic name of Posicor?

MIBEFRADIL is the generic (nonproprietary) name of Posicor.

Last reviewed 2026-04-20 · How we verify

Posicor (MIBEFRADIL)

FDA-approved withdrawn Small molecule Quality 35/100

At a glance

Generic name	MIBEFRADIL
Drug class	mibefradil
Target	Voltage-dependent T-type calcium channel subunit alpha-1I
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1997

Approved indications

Angina pectoris
Hypertensive disorder

Common side effects

No common side effects on file.

Drug interactions

alfuzosin
silodosin
tamsulosin
terfenadine

Key clinical trials

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM (PHASE1)
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma (PHASE1)
Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Posicor CI brief — competitive landscape report
Posicor updates RSS · CI watch RSS